Bausch + Lomb Rings Bell On 'Largest' Launch Year

Canadian firm’s eye health supplements Occuvite and PreserVision remain top sellers, with ReNu and Biotrue contact lens solutions and Lumify eye drops and skin care line rounding out its top 10 revenue generators.

• Source: Shutterstock

Bausch + Lomb Corp. says its 2023 results “set the tone” for its "largest" year for product launches in 2024 but the sound investors likely want to hear most is the completion of its separation from majority owner Bausch Health Companies Inc.

The Canadian firm’s eye health dietary supplements Ocuvite and PreserVision continued as its top sellers in 2023 and in the...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Earnings

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Coty‘s Consumer Beauty Unit Will ‘Function Like A Startup’ To Launch More Products Quickly – Nabi

 

CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.

More from Business

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.